Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study

We identified substantial variation in the use of G-CSF within the practice. However, omission of G-CSF was not associated with treatment delays or adverse events. Prospective studies are warranted to formally test whether routine G-CSF is necessary during dose-dense T therapy.